AzTrials
AzTrials

Advanced Squamous Non-small Cell Lung CancerPhase 1sNSCLCNCT03808701

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

A Phase 1 study testing SCT200 in people with Advanced Squamous Non-small Cell Lung Cancer, run by Sinocelltech Ltd..

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs). Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
SCT200
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
No sites listed yet
Study dates
Mar 2019to Dec 2019
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Able to provide written informed consent and can understand and comply with the requirements of the study;
  • Men/Women from 18 to 75 years old;
  • Life expectancy of longer than 3 months ( clinical assessment);
  • With an Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
  • Histological or cytological diagnosis of Squamous non-small cell Lung cancer;
  • Locally advanced or metastatic NSCLC(stage IIIB/IV or recurrent NSCLC that do not meet the criteria for radical radiotherapy and chemotherapy，Tumor stage will be classified according to UICC/AJCC staging system version 8).Participants has received at least two previous chemotherapy regimens for treatment failure (including disease progression and unacceptable toxic and side effects).
Show all 10Show fewer
  • Note: a. first-line chemotherapy must be a platinum-containing two-drug regimen;b. Prior adjuvant/neoadjuvant chemotherapy is permitted.If recurrence or metastasis occurs during or within 6 months after the completion of adjuvant/neoadjuvant chemotherapy, it is considered that adjuvant/neoadjuvant chemotherapy is a first-line systemic chemotherapy failure for advanced disease." According to RECIST 1.1 , patients must have at least one measurable lesion that can be accurately assessed at baseline.
  • Adequate organ and marrow function as defined below:
  • Absolute neutrophil count (ANC) greater than/equal to 1.5×l09/L; Platelets greater than/equal to 75×109/L; Hemoglobin greater than/equal to 80g/L; Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than/equal to 3 times ULN, or less than/equal to 5 times ULN if known liver metastases; Total bilirubin less than/equal to 1.5 within institutional limit of normal (ULN); Serum creatinine less than/equal to 1.5 times ULN; Electrolyte: magnesium greater than/equal to normal.
  • -

Who cannot join

  • Patients are allergic to antibodies or other components contained in the test drugs;
  • Symptomatic metastatic central nervous system and/or cancerous meningitis.(After treatment for brain metastasis, disease should be stable and last for at least 4 weeks prior to the first study administration, not requiring for steroid or anticonvulsant therapy,Subjects with stable neurological symptoms may be enrolled ).For stable asymptomatic brain metastases that have been treated with radiotherapy, at least one other site besides the brain metastasis can be measured ,The subject can be enrolled, but the interval between the last radiotherapy should be more than 4 weeks..
  • Subject receiving bisphosphonate or denosumab treatment for bone metastases was initiated within 28 days prior to study. (If the subject has received bisphosphonate or denosumab treatment prior to study and showing stable time less than 28 days,the subject is allowed to use it.) If the ongoing bisphosphonate therapy dose is considered to be increased or bisphosphonate therapy is initiated due to the aggravation of bone pain, researchers should confirm whether the subject has PD according to the RECIST1.1 version.
  • Patients with other primary malignancies, except for before 5 years or more, malignant lesions had been treated with therapeutic measures and no known active lesions existed, and the researchers judged that the risk of recurrence was low;Non-melanoma skin cancer treated adequately without evidence of disease progression; cervical carcinoma in situ after adequate treatment;Prostate intraepithelial neoplasm, no evidence of recurrence of prostate cancer;
  • Patients administrated EGFR target treatment including EGFR TKI agent or anti- EGFR monoclonal antibody;
  • Within 4 weeks, patients received anti-tumor drugs (such as chemotherapy, hormone therapy, immune therapy, the antibody therapy, radiotherapy) or research drugs(42 days for nitrosourea or mitomycin C), or patients with grade 2 or more adverse reaction caused by previous anti-tumor therapy(except alopecia or neurotoxicity grade 2 or less);
Show all 19Show fewer
  • Patients are currently enrolled in other research devices or in research drugs, or less than 4 weeks from other research drugs or devices.
  • "Patients received major surgery(such as general anesthesia ) within 4 weeks ,or subjects did not recovered from the injury associated with the surgery.
  • Note: surgery requiring local/epidural anesthesia must have been completed for at least 72 hours and subjects must have recovered before starting the study medication.Skin biopsy under local anesthesia has been completed for at least 1 hour."
  • Patients treated with EPO, G-CSF or GM-CSF before enrollment 2 weeks.
  • Patients who have clinically significant cardiovascular disease (defined as unstable angina pectoris, symptomatic congestive heart failure (NYHA, greater than II), uncontrollable severe arrhythmia); Patients occurred myocardial infarction within 6 months.
  • Patients who have interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or on baseline chest CT or MRI reminder ILD .
  • Patients with clinical symptoms, required clinical intervention or stable time less than 4 weeks of serous cavity effusion (such as pleural effusion and ascites);
  • Patients with active hepatitis B or active hepatitis C, etc. (for patients with a history of hepatitis B, whether treated or not, HBV DNA ≥104 or ≥ 2000IU/ml, HCV RNA≥15IU/ml); HIV antibody positive (if there is no clinical evidence suggesting that there may be HIV infection, there is no need to detect);
  • Patients with uncontrolled active infections before enrollment 2 weeks (except simple urinary tract infection or upper respiratory tract infection);
  • Pregnant or lactating women(Serum test must be negative within 7 days prior to study enrollment)
  • Patients((including male or female subjects) who were not willing to accept effective contraceptive measures( intrauterine device, prophylactic or condom)during treatment and within 6 months after treatment;
  • Subjects who are considered unsuitable for participating in this study for various reasons at the discretion of the investigator，such as inability to comply with study and/or follow-up procedures;
  • -

Trial locations and contacts

No sites are listed yet.

CHENG YING, MD contact

0431-85872688

chengying@csco.org.cn

About this study

Official title: Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Advanced Squamous Non-small Cell Lung Cancer : a Phase Ib, Open-label, Multicenter Study

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs).

Read the detailed description

This open label multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in Squamous non-small cell Lung cancer treated with anti-EGFR monoclonal antibody SCT200.

Being tested
SCT200
Keywords
SCT200, Squamous non-small cell Lung cancer, NSCLC

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SCT200Drug

    Recombinant Anti-EGFR Monoclonal Antibody

Study groups in NCT03808701
Study groupRoleWhat they receive
low dose groupExperimentalInitially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
Receives: Drug: SCT200
HIGH dose groupExperimentalInitially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
Receives: Drug: SCT200

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response rate (ORR)

    ORR is defined as proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 during trial treatment.

    Measured: 1 year

Secondary outcomes (7)

  1. Progress Free Survival ( PFS)

    PFS is defined as the time from first dose of SCT200 until the date of first documentation of progression or date of death, whichever occurs first,according to RECIST v1.1 criteria.

    Measured: 1 year

  2. Disease control rate (DCR)

    The achievement of any a stable response（SD）, partial response (PR) or complete response (CR), according to RECIST v1.1 criteria.

    Measured: 1 year

  3. Duration of response (DOR)

    DOR is defined as time from the date when a patient first meets the criteria for CR or PR according to RECIST v1.1, until the date that progressive disease (PD) is objectively documented or death, whichever occurs first.

    Measured: 1 year

  4. Overall survival (OS)

    OS is defined as time from first dose of SCT200 until the date of death from any cause.

    Measured: 1 year

  5. AE

    AE are assessed according to NCI CTCAE v4.03.

    Measured: 1 year

  6. Evaluation of immunogenicity

    Serum SCT200 antibody levels were measured before and after administration.

    Measured: 1 year

  7. exploratory analysis

    To explore the possible correlation between EGFR and/or related gene expression and disease prognosis and therapeutic efficacy

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2019
  2. Study startMar 2019 (estimated)
  3. Primary completionDec 2019 (estimated)
  4. Study completionDec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03808701
Sponsor's protocol ID
SCT200-D101
Acronym
sNSCLC
Status last verified
Jan 2019
First submitted
16 Jan 2019
Last updated
17 Jan 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing SCT200 in people with Advanced Squamous Non-small Cell Lung Cancer, run by Sinocelltech Ltd..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact CHENG YING, MD (0431-85872688, chengying@csco.org.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective response rate (ORR) (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03808701.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in